Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Daxor Corp (DXR)

Daxor Corp (DXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,693
  • Shares Outstanding, K 4,735
  • Annual Sales, $ 1,450 K
  • Annual Income, $ -7,190 K
  • 60-Month Beta -0.46
  • Price/Sales 36.22
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade DXR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.11 +18.99%
on 03/27/24
9.94 -2.92%
on 04/25/24
+1.02 (+11.88%)
since 03/26/24
3-Month
7.19 +34.21%
on 03/05/24
9.94 -2.92%
on 04/25/24
+1.05 (+12.21%)
since 01/26/24
52-Week
7.11 +35.72%
on 11/29/23
13.13 -26.49%
on 05/19/23
-1.50 (-13.41%)
since 04/26/23

Most Recent Stories

More News
DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICE

New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by...

DXR : 9.65 (unch)
DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICE

New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by...

DXR : 9.65 (unch)
Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients

Oak Ridge, TN, May 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces...

DXR : 9.65 (unch)
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today...

DXR : 9.65 (unch)
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference

Oak Ridge, TN, March 23, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces...

DXR : 9.65 (unch)
Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure

Daxor’s BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure Oak Ridge, TN, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Daxor...

DXR : 9.65 (unch)
Daxor Corporation Commences Trading on The NASDAQ Capital Market

Management to Ring the Nasdaq Stock Market Opening Bell on February 4, 2022 Oak Ridge, TN, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...

DXR : 9.65 (unch)
Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors

Oak Ridge, TN, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announced today...

DXR : 9.65 (unch)
Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022

Oak Ridge, TN, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces...

DXR : 9.65 (unch)
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces...

DXR : 9.65 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Daxor Corporation is a medical device manufacturing corporation with additional biotech services.

See More

Key Turning Points

3rd Resistance Point 10.19
2nd Resistance Point 10.07
1st Resistance Point 9.86
Last Price 9.65
1st Support Level 9.52
2nd Support Level 9.40
3rd Support Level 9.19

See More

52-Week High 13.13
Fibonacci 61.8% 10.83
Fibonacci 50% 10.12
Last Price 9.65
Fibonacci 38.2% 9.41
52-Week Low 7.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar